ACCEL DIAGNOSTICS, LLC

ACCEL DIAGNOSTICS, LLC specializes in translational research and development focused on diagnostic technologies for cardiotoxicity assessment in oncology patients. Their core expertise lies in designing minimally invasive diagnostic assays that detect early biomarkers of chemotherapy-induced cardiac damage, leveraging advanced molecular diagnostics, bioanalytical validation, and clinical data integration. The company’s technical capabilities include biomarker discovery, assay development for low-volume clinical samples, and validation of point-of-care diagnostic platforms compliant with clinical laboratory standards. Their work bridges laboratory innovation with clinical applicability, emphasizing patient safety in cancer therapy through precision monitoring tools. A key differentiator is their focus on non-invasive, high-sensitivity detection methods that reduce patient burden while improving therapeutic decision-making. The contractor has demonstrated direct experience supporting the Department of Health and Human Services, specifically through SBIR Phase II funding initiatives focused on high-impact health technologies. Their engagement with HHS reflects a targeted alignment with NIH and FDA priorities in early diagnostic innovation, particularly in oncology and cardio-oncology. The relationship suggests a pattern of collaboration on federally funded research programs aimed at translating preclinical findings into clinically viable diagnostic solutions. ACCEL DIAGNOSTICS operates primarily under NAICS 541715, which encompasses applied research in life sciences excluding biotechnology and nanotechnology. In practice, this means they develop analytical tools and diagnostic protocols grounded in biochemical, pharmacological, and clinical science—positioning them as a niche player in the precision diagnostics market for oncology support therapies. Their market focus is on bridging the gap between academic research and regulatory-ready medical devices. As a small business structured as a 2L entity based in Houston, Texas, ACCEL DIAGNOSTICS is positioned as a specialized R&D firm without formal government certifications. Their geographic presence supports regional life sciences ecosystems, and their government market positioning centers on competitive SBIR/STTR programs that fund high-risk, high-reward diagnostic innovations.